title: Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction.
abstract: Since according to the early studies, the outcome after splenectomy in the individual patient with myelofibrosis with myeloid metaplasia (MMM) is unpredictable, we assessed retrospectively the pre-intervention characteristics that best predicted adverse events, hematological consequences, and survival in 71 splenectomized MMM patients. The findings indicate that the operative risk of splenectomy for both mortality (8.4%) and morbidity (39.3%) was unpredictable. New hemorrhagic or thrombotic complications occurred in 16.9% of surviving patients and were predicted by age < 50 years, a normal to high platelet count (> 200 x 10(9)/l) and huge splenomegaly (> 16 cm from the costal margin). Massive liver enlargement occurred in 24% of patients and has to be expected in patients splenectomized for transfusion-dependent anemia. Anemia improved substantially in 45% and 52% of patients at 3 months and at 1 year, respectively, and was predicted by severe anemia, low platelet count (< 100 x 10(9)/l) or normal to high white blood cell (WBC) count (> 4 x 10(9)/l). Survival from splenectomy was superior in patients < 45 years with WBC < 10 x 10(9)/l count. An unexpectedly high rate of blastic transformation was observed. It accounted for 42.8% of the deaths. The results suggest trials for prophylactic cytoreductive treatment in young patients and when platelet count is normal to increased. Further study is needed for elucidating the possible role played by splenectomy in inducing blastic transformation.
authors.affiliation: Dipartimento di Medicina Interna e Terapia Medica, IRCCS Policlinico S. Matteo, Pavia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Barosi
authors.forename: A
authors.initials: A
authors.lastname: Ambrosetti
authors.forename: A
authors.initials: A
authors.lastname: Buratti
authors.forename: C
authors.initials: C
authors.lastname: Finelli
authors.forename: N L
authors.initials: NL
authors.lastname: Liberato
authors.forename: S
authors.initials: S
authors.lastname: Quaglini
authors.forename: M M
authors.initials: MM
authors.lastname: Ricetti
authors.forename: G
authors.initials: G
authors.lastname: Visani
authors.forename: S
authors.initials: S
authors.lastname: Tura
authors.forename: E
authors.initials: E
authors.lastname: Ascari
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D001803:Blood Transfusion; D005260:Female; D006441:Hemoglobin A / Q000378:metabolism; D006470:Hemorrhage / Q000209:etiology; D006529:Hepatomegaly / Q000209:etiology; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008679:Metaplasia / Q000097:blood / Q000401:mortality / Q000601:surgery; D008875:Middle Aged; D010976:Platelet Count; D055728:Primary Myelofibrosis / Q000097:blood / Q000401:mortality / Q000601:surgery*; D013154:Spleen / Q000473:pathology*; D013156:Splenectomy / Q000009:adverse effects / Q000401:mortality; D016019:Survival Analysis; D013927:Thrombosis / Q000209:etiology
chemical_list: D006441:Hemoglobin A